Alon Ironi, CEO and co-founder of Theranica, the company’s offering in digital therapeutics.
Combining innovative neuromodulation therapy with wireless technology, product Nerivio is developed, a smartphone-controlled wearable therapeutic electroceutical device that harnesses the body’s endogenous pain regulation mechanism to address migraine pain. Nerivio, which is FDA-cleared for the acute treatment of both episodic and chronic migraine, is a drug-free alternative to traditional migraine treatments.
Together with Dr. Shimon Eckhouse, Ronen Jashek and Rostislav Barabech, Theranica was born to address this disorder through the lens of modern technology and innovation. Investigating the migraine treatment space and identified the need for a drug-free, non-invasive and low side-effect solution that would be affordable for patients. With Dr. Yarnitsky’s research and guidance in developing Nerivio, a smartphone-controlled REN wearable for acute migraine treatment.
Migraine is the third most prevalent disorder in the world, affecting roughly 1 billion people globally. Migraine and headache pain are leading causes of outpatient and emergency department visits, and remain a critical public health problem, particularly among women during their reproductive years, who are disproportionately affected by migraine.
Nerivio is unique among migraine therapies as it provides a totally non-pharmacological, non-invasive, safe and effective alternative to medication. Nerivio is a therapeutic wearable device placed on the upper arm, which uses REN technology to alleviate pain by stimulating the brain’s endogenous pain inhibition mechanism known as Conditioned Pain Modulation (CPM). It is clinically proven, based on numerous clinical studies and six peer-reviewed scientific publications, showing that Nerivio is non-inferior to prescribed medications in the market. The Nerivio app allows the user to personalise each treatment depending on the intensity of the pain and enables easy tracking of migraine triggers through the user-friendly migraine diary.
Source: www.med-technews.com